When the final article is assigned to volumes/issues of the Journal, the Article in Press version will be removed and the final version appear in the associated published volumes/issues of the Journal. The date the article was made available online first will be carried over. 2 Comorbidity as a factor of prognosis in patients with locoregionally advanced, inoperable squamocellular head and neck cancers (HNSCC) Komorbiditet kao prognostički faktor u bolesnika sa lokoregionalno uznapredovalim, inoperabilnim planocelularnim karcinomima glave i vrata Abstract Background/Aim: Patients with tumours often have other diseases or conditions in
of pts without comorbidities and those with grade 2 and 3 taken together (p=0.0047).
Results of other intergroup comparisons were of no statistic significance.
Conclusion: Comorbidity is important prognostic variable in patients with locoregionally
advanced HNSCC and should be properly assessed prior to therapy. Rezultati: Komorbiditet je bio prisutan u 69 bolesnika (69%) dok 31 bolesnik (31%) nije imao komorbidnih stanja pre početka lečenja. Najčešća komorbidna stanja odnosila su se
Introduction
Head and neck squamous cell carcinomas (HNSCC) include a wide range of malignant tumours that originate in the different structures of this region of the body. This tumour type is the sixth most common malignancy worldwide, accounting for about 6 % of all cancer cases and responsible for an estimated 1-2% of all cancer deaths. Oral cavity and laryngeal cancers are the most frequent globally, with age-adjusted standardized incidence rate of 3, 9 and 2,3 per 100 000 respectively 1,2 . Similar situation is in our country with HNSCC incidence rate of 7% and larynx cancer as the most common entity 3 .
Although not leaders in the field of oncology, HNSCC are important because their presentation can cause aesthetic alterations of the face and neck with disturbance of vital functions such as a breathing, swallowing, phonation and hearing. Besides HNSCC, tobacco and alcohol use is also associated with the development of other medical conditions ranging from cardiovascular to psychiatric disorders. So, many middle-aged patients with head and neck cancers present with a variety of coincident diseases which are known as comorbidities 5 . From practical point of view, comorbidity in oncology could be defined as any co-existing medical disorder unrelated to the index cancer. The concept of comorbidity and its prognostic importance was first developed from early works of Alvin Feinstein who first had studied the influence of comorbid conditions in patients with diabetes mellitus 6, 7 . Although not a feature of cancer itself, comor bidity is a relevant attribute of the patient and may adversely affect his/her quality of life and survival 8 . It is common among patients with HNSCC and incidence of moderate and serious conditions in this particular population is about 25% portending higher mortality risk 9, 10 . So, careful pretherapy assessment of comorbidity should help in treatment decision making and proper utilization of health care resources.
Our study focused on the impact of patient conditions classified using ACE-27 index (Adult Comorbidity Evaluation index) in population with locoregionally advanced, inoperable head and neck cancers treated initially with neoadjuvant chemotherapy. Our aim was to evaluate the prevalence of comorbidities, most frequent conditions among them and prognostic influence on overall survival in this group of patients. Before treatment patients were presented to multidisciplinary oncology team for proper decision making.
Methods
In our prospective, randomized, clinical phase III study, patients received neoadjuvant chemotherapy with 3 drugs. Randomisation was performed electronically, and first group received Cytosin-arabinoside a 500 mg/ m 2 (D1), 5fluorouracil a 750 mg/m 2 (D1-5) given as a 4-hour infusion, and Cisplatin a 120 mg/m 2 (D1). The second group received the same regimen with 5fluorouracil given continuously (120 hours). All drugs were applied intravenously.
The aims of the study were to assess the overall survival and efficacy of therapeutic The Cox proportional hazards regression was used to investigate the independent effects od ACE-27 scoring on survival.
Results
Within a period of 54 months we analysed 100 patients with a poor prognosis HNSCC of whom 91 were men and 9 women. The median age for the whole group was 55 years (range 37-75 years).
Tumours were dominantly located in the hypopharynx (46%), then oropharynx (30%) and larynx (20%) while epipharyngeal and sinonasal tumours much less occurred.
(4%). Most tumours were locally advanced either T3 (21%) or T4 (68%) and regarding the nodal neck metastatses most patients had high nodal volume disease -N3 (62%) while bilateral neck metastatses -N2C were found in 38 patients (38%). Tumour tissue in over two thirds of patients (72%) was of moderately differentiated histological grade (grade 2).
Chemoregimen with continuous 5fluorouracil infusion was given to 59 patients (59%) while 41 of them (41%) had received short infusion (4 hours). The median number of given cycles was 4 (range 1-6).
The response rate (CR+PR) with therapy was achieved in 45 patients (45%) and 44 patients (44%) had progressed during the chemotherapy. Disease control rate (CR+PR+SD) was observed in 56 patients (56%) ( Table 1 ).
The median time of surveillance was 12 months.
About one third of patients (31%) was without comorbid conditions while 69 patients (69%) had some kind of concommitant disorders. The most frequent among them was alcoholism (active and previous) which was present in 49 patients (71 %). The next category of comorbid conditions belongs to the chronic pulmonary diseases and was noted in 25 patients (36%), and the third were cardiovascular diseases present in 18 patients (26%) with arterial hypertension as a leading condition. Among gastrointestinal disorders, chronic hepatic disease was present in 9 patients (13%), and diabetes mellitus was present in 10 patients (14%). The other comorbid conditions have been encountered much less frequent ( Table 3 ).
The comorbidity was measured using ACE-27 index with most frequently observed score being gr. I (mild) in 43 % of patients, while grades II (moderate) and III (severe) were present in 20% and 6% of them respectively. (Table 4) Median overall survival for the whole group was 12 months (Fig 1) .
Patients without comorbitities have survived significantly longer (16 months vs 11
months) in comparison with their counterparts who had any kind of a comorbid condition (p=0.0089).
Comparing the different pairs of comorbidity categories, there is no significant difference in overall survival between patients without comorbidities and those with mild ones. The same situation is between dose with mild comorbidities and patients with moderate and severe conditions taken together. However, patients without comorbidities survived longer in comparison to those with moderate and severe conditions taken together (p=0.00474).
Discussion
Being the most respected clinical skill in the past centuries, medical prognosis regained its importance in the present era of personalized medicine.
The influence of comorbidity on survival in patients with cancer may be direct in relation with heavier disease burden,or indirect through the choice and timing of proper anticancer treatment thus many recent works show the clinical significance of comorbid conditions in oncology 11, 12 , 13 .
Because of toxic effects of tobacco and alcochol, patients with head and neck cancers are especially likely to have various comorbid health conditions thus serving as a good model for investigating the relationship between comorbidity and survival. Indeed, in the past 15 years many authors have confirmed strong prognostic impact of associate illnesses in head and neck oncology 14, 15 .
Our study is unique in a way that it deals exclusively with patients who have advanced, inoperable cancers initially treated with neoadjuvant chemotherapy. Most of them were predictably males. As one may expect, majority of patients had their primaries in hypopharynx, oropharynx and larynx with N3 nodal stage, which is in accordance with most recent epidemiological data 16 .
The median time of surveillance in our series was 15 months with range of 3-59 months which is much longer than in the pivotal work of Piccirillo, published in 2000 year 5 . Such a follow-up can provide a fair amount of information.
In our study alcocholism (former and active) prevails being present in 71% of patients with comorbid conditions which could be explained by the fact that alcochol abuse may lead to addiction but also is the causative factor in most of HNSCC cases. The other reason might be the specific separation and inclusion of this condition in the ACE-27 scoring index. The second most prevalent group of conditions are pulmonary diseases observed in 36% of our population, while cardiovascular diseases with preponderance of the arterial hypertension are on the third place (26%). Of note is the absence of angina pectoris among our patients for which we do not have a plausible explanation. So, alcocholism aside our data are in concordance with results of Vlahiotis and Piccirillo 17 .
The most common score of comorbidity in our patients was grade I (mild) present in 43% of cases, while grades II (moderate) and III (severe) were present in about quarter of patients. In Datema's large study, results are partly different with smaller percentage of mild comorbidity (17%) while moderate (13,5%) and severe grades (6%) were much more in accordance with our results 18 . However, among Datema's patients the vast majority (74%) had localized or locoregional disease (TNM stages I and II) where prognosis is better and presence of comorbid ailments is not so prominent.
In our series 31% of patients were without any kind of comorbid diseases, and quite predictably they survived significantly longer compared with their counterparts with some kind of comorbidity (p= 0.0089). Similar results although on far larger scale were obtained by Land and Patnaik analyzing more than 60 000 women with breast cancer where those without comorbidities had much better overall survival 19, 20 . Another finding from our study which is of statistical significance referred to the fact that patients without comorbidities fare better in comparison to those with moderate and severe conditions taken together (p=0.00474). In statistical sense there is no difference in survival between patients with severe comorbidities and those with mild or moderate comorbidities.Although somehow paradoxical, this fact could be explained by the very small number of our patients with severe conditions (6%) which is not sufficient for any firm conclusion regarding the survival of this sole category. So, the only way to overcome this problem is to conduct large clinical studies properly designed to measure and explore the impact of various categories of comorbidity on survival of the patients with HNSCC.
The main limitations of our study are that it reflects the experience of patients at only one large academic institution, analyzing the only one end pointoverall survival. This is important because the patients treated in academic centers are in general younger, healthier and with smaller tumours. On the other hand, dealing exclusively with survival, other pertinent end points as quality of life may be missed.
Although it is well known fact that the relative impact of comorbidity tends to be greater for cancers with better prognosis, we demonstrated that even in poor prognostic population this prognostic variable still holds its importance.
Conclusion
The presence of comorbid illnesses is a frequent finding in patients with HNSCC.
The most prevalent conditions in our study are alcocholism, chronic pulmonary disorders and cardiovascular disorders. Those without comorbidities survive significantly longer in comparison to patients with some kind of associated ailment, particularly of moderate and severe intensity. So, proper measurement of comorbid conditions in patients with HNSCC before treatment is strongly recommended. 
